Key Transcription Factors Involved in Cardiac Conduction System: History
View Latest Version
Please note this is an old version of this entry, which may differ significantly from the current revision.
Contributor:
Ridwan Opeyemi Bello
,
Shannon Frew
,
Yusra Siddiqui
,
Rashid Minhas

The heart is composed of muscle cells called cardiomyocytes, including a specialized population named pacemaker cells that form the cardiac conduction system (CCS), which is responsible for generating the action potential dictating heart contractions. Failure of the CCS system leads to cardiac arrhythmias, which require complicated therapies and often the surgical implantation of electrical pacemakers. 

  • cardiac conduction system
  • pacemaker
  • gene regulatory network

1. Contracting Cardiac Muscle

The heart, a muscular organ, orchestrates blood circulation throughout the body by generating and coordinating electrical impulses. These impulses are controlled by the cardiac conduction system (CCS), which consists of myogenic components that regulate the contractions of the atria and ventricles [1][2][3][4]. In higher vertebrates, the CCS is divided into specific regions: the slow-conducting structures, such as the sinoatrial node (SAN); the primary site for pacemaker cardiomyocytes (CMs), often referred to as the “natural pacemakers” of the heart, which are located between the superior vena cava and the right atrium; the secondary pacemaker, the atrioventricular node (AVN), which is situated within the atrioventricular septum; and the fast-conducting ventricular conducting system (VCS), which includes the atrioventricular bundle (AVB, also known as the His-Bundle), the right and left bundle branches (BBs), and the Purkinje fiber network (PFN) (which is responsible for ventricular coordination) [3][5][6]. Pacemaker cells within the CCS are a specialized population with a unique and vital role. They have the remarkable capability to spontaneously generate regular electrical impulses, effectively setting the pace for the entire heart. These rhythmic depolarization and repolarization cycles in pacemaker cells are responsible for initiating each heartbeat and maintaining its regularity [4]. These electrical signals rapidly travel through the atrial cardiomyocytes, thus initiating atrial contraction [7]. Subsequently, they navigate through slower-conducting tissues within the AVN, introducing a deliberate delay before transmitting to the His-Purkinje fibers, thereby effectively coordinating ventricular contraction [4][8] (Figure 1).
Muscles 02 00026 g001
Figure 1. Cardiac contraction and the histology of cardiac muscle. (A) Schematic representation of the components of the cardiac conduction system (CCS) in a human heart. In the inset picture, a cross-section of the human heart muscle is shown with binucleated cardiomyocytes. The various components of the CCS (in green) are labeled: the sinoatrial node (SAN), found at the junction of the superior caval vein and right atrium, generates the impulse that then travels to the atrioventricular node (AVN). Propagation occurs through the left and right bundle branches of His-Purkinje, leading to ventricular contraction. (B) An electrocardiogram representing the recording of the electrical activity of the heart. The upper chambers of the heart (atria) begin to beat when the first wave of the ECG, labeled P, appears. The lower chambers of the heart (ventricles) are represented by the QRS complex as an electrical current flow. The electrical current spreads back over the ventricles in the opposite direction during the recovery phase, which is represented by the T wave.
Cardiac muscle development is a complex and tightly regulated process involving the differentiation and specialization of various cell types, including CMs and pacemaker cells. Notably, diverse vertebrate species exhibit a remarkable spectrum of cardiac development timelines. In a developing human embryo, the initial indications of heart muscle contractions typically emerge around embryonic day 22, which marks the third week of gestation. This coincides with the evolution of the first heart field into the heart tube [9]. In comparison, mice exhibit an earlier onset of heart muscle contractions, typically occurring around embryonic days E8 to E9 [10][11]. However, zebrafish exhibit a unique timeline, possessing distinct heart muscle anatomy from humans, mice, or chickens. Contraction in zebrafish begins as early as 22 h after fertilization. In chickens, contraction initiates at approximately HH10 to HH11 [12][13][14], and each species reflects the intricacies of its cardiac development.
Studies from mammalian, avian, and fish model systems have shown that each CCS component consists of a specialized group of CMs with distinctive morphological and electrophysiological properties, as well as transcriptional profiles [15]. This specialized development of the CCS and pacemaker cells plays a pivotal role in establishing a fully functional heart. However, disruptions or defects in this developmental process can lead to cardiac arrhythmias, including conditions like Brugada syndrome, long QT syndrome, and sudden cardiac death [16][17]. These arrhythmias are characterized by irregular or slow heartbeats, thus ultimately compromising the heart’s ability to efficiently pump blood. Importantly, some of these arrhythmias can further complicate the treatment of congenital cardiac conditions, which often require therapeutics like ion channel blockers, or surgical interventions such as ablation or electronic pacemaker implantation [4]. However, the limitations associated with conventional pacemakers have highlighted the pressing need for alternative pacemaker solutions, leading to the emergence of biological pacemakers as a promising avenue for improving the management of cardiac arrhythmias.

2. Key Transcription Factors Involved in CCS Development

Exploring CCS development and homeostasis is reliant on transcriptional and regulatory networks that are embryonic-stage-dependent, dose-dependent, and tissue-dependent [18][19][20]. A cascade of transcription factors, SHOX2, BMP4, NKX2-5, ID2, ISL1, GATA4, HAND1, IRX3, and various T-box transcriptions factors are instrumental to the divergence in myocyte development. Below are sub-sections that show the evidence as to why these transcription factors are important.

2.1. Short Stature Homeobox 2 (SHOX2) and Bone Morphogenic Protein 4 (BMP4)

SHOX2 and BMP4 are recognized as pivotal factors contributing to the formation of the SAN, a critical element in heart rhythm regulation [4][21]. Dysfunction of the SAN can precipitate various cardiac arrhythmias, including bradycardic arrhythmias [22]. The SHOX2 transcription factor holds essential significance in both SAN development and differentiation. Its wide expression throughout the body, including the heart muscle, underscores its multifaceted role [22]. Conversely, BMPs, a subgroup of signaling molecules within the Transforming Growth Factor β superfamily, play a vital role in pacemaker development. BMP4, in particular, assumes a central position in embryonic heart development by promoting fibroblast reprogramming into cardiomyocytes with pacemaker activity [23]. Notably, SHOX2 exerts influence over BMP4, where their expressions overlap [24]. Among the remarkable functions of BMP4 are that it takes a lead role in driving the differentiation of cardiac pacemaker cells [25]. Illumination from epistatic genetic experiments conducted in Xenopus has unveiled a direct interaction between SHOX2 and the BMP4 promoter. The closely coordinated expression patterns of BMP4 and SHOX2 are especially conspicuous in the SAN during embryonic development [24].

2.2. T-Box Transcription Factor 5 (TBX5), NK2 Homeobox 5 (NKX2-5), and Inhibitor of DNA Binding 2 (ID2)

TBX5, NKX2-5, and ID2 play indispensable roles in the development of the atrioventricular bundle and bundle branches [4][26]. The transcription factor TBX5, while having diverse functions across the body, holds a pivotal role in cardiac development [26]. Mutations in TBX5 have been associated with cardiac defects in the septa and CCS. During early embryonic cardiac development, TBX5 functions as a transcriptional activator for genes involved in cardiomyocyte maturation [26]. In later cardiac development stages, TBX5 shifts its focus to the structure of the CCS and the maintenance of cardiomyocyte maturation [26]. NKX2-5, a cardiac homeobox transcription factor with an expression spanning the cardiac system, plays a crucial role in regulating cardiac development and function [27]. Mutations in NKX2-5 result in cardiac defects and atrioventricular conduction irregularities. Throughout cardiac development, NKX2-5 is instrumental in regulating the function of working and in conducting myocytes within the atria, often in coordination with the Notch signaling pathway [27]. ID2, another cardiac transcription factor, is initially detected in areas like the neural crest, in inflow and outflow tracts, and in neurons around the aorta and pulmonary artery [28][29]. In later developmental stages, ID2 expression becomes apparent in the atrioventricular bundle around E12.5 and subsequently in the bundle branches by, approximately, E16.5 [26][29].

2.3. T-Box Transcription Factor 3 (TBX3)

TBX3, a vital player within the CCS, is integral for repressing atrial differentiation and maintaining proper cardiac function [30]. Various studies have linked noncoding variants near TBX3 expression to alterations in PR interval and QRS duration, underscoring its impact on atrioventricular conduction [31][32][33][34][35][36]. TBX3 is primarily found in the SAN, which is a part of the heart’s electrical system. It plays a major role in regulating the genes active in the SAN while actively suppressing genes associated with atrial function, ensuring that the SAN retains its pacemaker function and does not become atrial tissue [4]. When TBX3 is introduced where it is not typically found, it prompts the development of functional pacemaker cells within the atria [37][38]. In essence, TBX3 transforms regular cardiac cells into pacemaker-like cells within its domain of influence.
In the nearby developing atrial heart tissue, Nkx2-5 has an opposing role. Nkx2-5 represses the expression of TBX3 and another gene called Hcn4. This is consistent with observations in embryos lacking Nkx2-5, which show abnormal expressions of TBX3 and Hcn4 in the heart tube [39]. Conversely, introducing extra Nkx2-5 into heart muscle cells, including those in the SAN, prevents the proper formation of the SAN [40]. This indicates that Nkx2-5 acts to confine the influence of TBX3 and Hcn4 to specific areas of the heart.
Interestingly, the absence of Nkx2-5 in the SAN, while present in other heart muscle cells, provides a valuable tool for identifying SAN cells in laboratory-grown human ESCs. When scientists coax human ESCs into becoming heart cells, they produce both cells similar to those found in the heart’s chambers (NKX2-5+) and pacemaker-like cells that lack NKX2-5 expression (NKX2-5−) [41]. This research enhances our understanding of cardiac development and the roles of these critical transcription factors.

2.4. T-box Transcription Factor 18 (TBX18)

TBX18 plays a pivotal role in heart muscle development, particularly in shaping the structure and formation of the SAN [25][42]. Its expression is essential for early SAN specification, and it generates pacemaker activity during the initial phases of embryonic heart muscle formation [30][43][44]. Surprisingly, when Tbx18 is deficient in mice (which leads to underdeveloped sinus venosus and SAN structures), these mice do not display significant bradycardia (slow heart rate). Intriguingly, even in the presence of this deficiency, the SAN gene program remains intact in their underdeveloped SANs. This suggests that while Tbx18 may not directly control the SAN gene program, it plays an essential role in ensuring the proper formation and deployment of progenitor cells [30]. However, when Tbx18 is artificially introduced into ventricular myocytes via a viral method, it has a distinct impact. Specifically, it reduces the expression of connexin 43 (Cx43), a protein responsible for gap junction intercellular communication between cells, which regulates cell death, proliferation, and differentiation (while not affecting Cx40 and Cx45), in these ventricular myocytes [45]. In the ventricles of pigs and guinea pigs, the introduction of Tbx18 leads to a phenomenon called ‘reprogramming,’ where ventricular myocytes start to exhibit pacemaker-like properties and generate ectopic pacemaker activity. Alongside this reprogramming, there is a suppression of Cx43 and natriuretic peptide A (Nppa), as well as an increase in Hcn4 expression [46][47]. It is speculated that the differences observed between the loss and gain of Tbx18 function experiments can be attributed to the fact that Tbx18, which primarily acts as a repressor T-box factor [48], mimics the function of Tbx3 when overexpressed [4].

2.5. ISLET-1 (ISL1)

ISL1, a transcription factor, fulfills diverse roles across multiple organs during embryonic development, and, within cardiac development, it serves as a marker for second heart field progenitors [49]. Its expression is detectable as early as E7 in mouse heart development, and its pattern shifts as development progresses, with the expression being observed in the SAN from postnatal stages through to adulthood [50]. In zebrafish, Isl1 is a marker for pacemaker cells located at the junction of the sinus venosus and atrium, where it is necessary for normal pacemaker function and development [51]. In mice, Isl1 is indispensable for the proliferation and proper functioning of SAN cells, and its specific deletion within the SAN results in embryonic lethality [21]. Notably, the absence of Isl1 in mice leads to the downregulation of the key regulators involved in SAN development, such as TBX3, SHOX2, and BMP4, as well as ion channels that are crucial for SAN function, including HCN4, HCN1, and Cacna1g [21][52]. Conversely, when Isl1 is overexpressed in the cardiomyocytes derived from ESCs, it upregulates the genes associated with the SAN while downregulating genes linked to chamber myocardia [53]. Remarkably, Isl1 is a target of SHOX2 within the SAN, and it can rescue the bradycardia phenotype that results from SHOX2 deficiency [54]. This emphasizes the pivotal role of ISL1 in the development and regulation of pacemaker cells within the heart’s SAN.

2.6. GATA4

GATA4 functions as a crucial regulator of cardiomyocyte proliferation and differentiation. It exhibits high expression levels until birth and remains detectable in all cardiomyocytes [55]. It persists in its expression until approximately one week after birth, remaining easily detectable in cardiomyocytes and other cardiac cells, including those within the outflow tract (OFT), septa, and valves [55]. However, the absence of GATA4 in mice leads to embryonic lethality at E8.5, which is accompanied by cardia bifida, underscoring its crucial function in early heart formation [55][56]. Different studies have employed conditional knockout models. These models have shed light on GATA4’s dosage-sensitive role. Introducing LoxP sites to the GATA4 gene results in decreased expressions of around 20%, leading to structural heart defects [57]. Deleting GATA4 from cardiomyocytes using the Nkx2.5-Cre driver, occurring around E9.5, leads to myocardial thinning, the absence of mesenchymal cells in the endocardial cushions, a hypoplastic right ventricle, and embryonic lethality by E11.5 [58]. In contrast, the removal of Gata4 from endocardial cells through the Tie2-Cre driver results in embryonic lethality at E12.5 due to impaired epithelial-to-mesenchymal transformation (EMT), thus contributing to underdeveloped atrioventricular cushions [59]. Although GATA4 deletion when using the βMHC-Cre driver at E17.5 results in viable and fertile mice, it makes them susceptible to left ventricular dysfunction and dilation [60]. These findings underscore GATA4’s multifaceted role in regulating various aspects of cardiac development, including pacemaker cell development, as well as emphasize its importance in maintaining proper cardiac function.
On the other hand, GATA6 plays a pivotal role in the development of the SAN. Mutations in the GATA6 gene can lead to dysfunction in SAN patterning and size, ultimately contributing to the occurrence of arrhythmias [61]. This includes reduced levels of essential regulators for pacemaker cells like TBX3 and TBX5, which are accompanied by an increase in genes associated with the atria, such as Nkx2.5 and Nppa. Additionally, the arrangement of the SAN seems disturbed, particularly in the loss of HCN4+ pacemaker cells, which are mainly present in the head region [61]. While GATA6’s involvement in pacemaker cell differentiation is clear, it appears to have different functions depending on the type of cells within the SAN. In ISL1+ myocytes and HCN4+ conduction cells, GATA6 acts as an activator for the genetic program needed for pacemaker cell differentiation. It functions upstream of various transcriptional regulators in the SAN, including TBX3, TBX5, and TBX18 [61]. On the contrary, in endothelial cells, GATA6 probably regulates pacemaker cell differentiation indirectly, potentially through the influence on paracrine factors like EDN1, which plays a role in SAN cell differentiation [62]. An analysis of transcripts showed reduced levels of both EDN1 and one of its receptors, EDNRB, in the hearts of Gata6+/− mice as early as E11.5. This suggests that one way in which GATA6 contributes to the regulation of pacemaker cell differentiation in these cells is by modulating the activity of EDN1 [61].

2.7. HAND1

HAND1 plays a critical role in the specification and differentiation of embryonic structures, including the cardiac muscle of the heart [63]. It functions as an essential regulator for determining the fate of cardiac precursor cells, and it is involved in morphogenesis—a process controlled by the BMP signaling pathway [64]. Mutations in the HAND1 gene have been linked to congenital heart disease, highlighting its significance in heart development [65][66]. Moreover, recent research has revealed that BMP signaling can activate HAND1 regulation, further illuminating its role in heart muscle development [63].

2.8. IRX3

IRX3 plays a crucial role in regulating rapid electrical propagation within the ventricular conduction system by facilitating the transcription of Cx40 and Cx43 genes [67]. The development of the ventricular conduction system is tightly controlled by the activation of various transcription factors, including NKX2-5, TBX3, TBX5, and ID2 [26][67][68][69][70][71][72]. The dysregulation or loss of these transcription factors can result in a range of cardiac defects, particularly NKX2-5 and TBX5 loss, which can elevate the risk of arrhythmias [67]. IRX5 exhibits a gradient of expression within the ventricular myocardium, with the epicardium showing lower expression and the endocardium displaying higher expression levels [73]. Mutations in IRX5 are associated with an increased susceptibility to arrhythmias due to abnormal repolarization in the ventricular conduction system, which is influenced by the absence of a homeostatic Kv4.2 gradient [73][74].
The identification and understanding of the transcription factors involved in cardiac development, particularly in the context of the CCS, play a pivotal role in bridging the gap between existing knowledge and the practical applications in reprogramming strategies. Understanding the transcription factors’ roles in cardiac development provides a roadmap for designing targeted reprogramming approaches. By harnessing these insights, the efficiency and effectiveness of reprogramming strategies can be optimized, bringing us closer to the practical application of biological pacemakers and other therapeutic interventions for cardiac conduction disorders.

This entry is adapted from the peer-reviewed paper 10.3390/muscles2040026

References

  1. Cheng, G.; Litchenberg, W.H.; Cole, G.J.; Mikawa, T.; Thompson, R.P.; Gourdie, R.G. Development of the cardiac conduction system involves recruitment within a multipotent cardiomyogenic lineage. Development 1999, 126, 5041–5049.
  2. Meilhac, S.M.; Esner, M.; Kelly, R.G.; Nicolas, J.F.; Buckingham, M.E. The clonal origin of myocardial cells in different regions of the embryonic mouse heart. Dev. Cell 2004, 6, 685–698.
  3. Mohan, R.; Boukens, B.J.; Christoffels, V.M. Lineages of the Cardiac Conduction System. J. Cardiovasc. Dev. Dis. 2017, 4, 5.
  4. van Weerd, J.H.; Christoffels, V.M. The formation and function of the cardiac conduction system. Development 2016, 143, 197–210.
  5. Davies, F. The Conducting System of the Vertebrate Heart. Br. Heart J. 1942, 4, 66–76.
  6. Bhattacharyya, S.; Munshi, N.V. Development of the Cardiac Conduction System. Cold Spring Harb. Perspect. Biol. 2020, 12, a037408.
  7. Kennedy, A.; Finlay, D.D.; Guldenring, D.; Bond, R.; Moran, K.; McLaughlin, J. The Cardiac Conduction System: Generation and Conduction of the Cardiac Impulse. Crit. Care Nurs. Clin. N. Am. 2016, 28, 269–279.
  8. Moorman, A.F.; de Jong, F.; Denyn, M.M.; Lamers, W.H. Development of the cardiac conduction system. Circ. Res. 1998, 82, 629–644.
  9. Tan CM, J.; Lewandowski, A.J. The Transitional Heart: From Early Embryonic and Fetal Development to Neonatal Life. Fetal Diagn. Ther. 2020, 47, 373–386.
  10. Andres-Delgado, L.; Mercader, N. Interplay between cardiac function and heart development. Biochim. Biophys. Acta 2016, 1863, 1707–1716.
  11. Lindsey, S.E.; Butcher, J.T.; Yalcin, H.C. Mechanical regulation of cardiac development. Front. Physiol. 2014, 5, 318.
  12. Martinsen, B.J. Reference guide to the stages of chick heart embryology. Dev. Dyn. 2005, 233, 1217–1237.
  13. Wittig, J.G.; Munsterberg, A. The Chicken as a Model Organism to Study Heart Development. Cold Spring Harb. Perspect. Biol. 2020, 12, a037218.
  14. Xia, J.; Meng, Z.; Ruan, H.; Yin, W.; Xu, Y.; Zhang, T. Heart Development and Regeneration in Non-mammalian Model Organisms. Front. Cell Dev. Biol. 2020, 8, 595488.
  15. Anderson, R.H.; Yanni, J.; Boyett, M.R.; Chandler, N.J.; Dobrzynski, H. The anatomy of the cardiac conduction system. Clin. Anat. 2009, 22, 99–113.
  16. Barbuti, A.; Baruscotti, M.; DiFrancesco, D. The pacemaker current: From basics to the clinics. J. Cardiovasc. Electrophysiol. 2007, 18, 342–347.
  17. Cohle, S.D.; Suarez-Mier, M.P.; Aguilera, B. Sudden death resulting from lesions of the cardiac conduction system. Am. J. Forensic Med. Pathol. 2002, 23, 83–89.
  18. Li, K.Y.C.; Cook, A.C.; Lovering, R.C. Going Forward With the Cardiac Conduction System Using Gene Ontology. Front. Genet. 2022, 13, 802393.
  19. Liang, W.; Han, P.; Kim, E.H.; Mak, J.; Zhang, R.; Torrente, A.G.; Goldhaber, J.I.; Marban, E.; Cho, H.C. Canonical Wnt signaling promotes pacemaker cell specification of cardiac mesodermal cells derived from mouse and human embryonic stem cells. Stem Cells 2020, 38, 352–368.
  20. Schram, G.; Pourrier, M.; Melnyk, P.; Nattel, S. Differential distribution of cardiac ion channel expression as a basis for regional specialization in electrical function. Circ. Res. 2002, 90, 939–950.
  21. Liang, X.; Zhang, Q.; Cattaneo, P.; Zhuang, S.; Gong, X.; Spann, N.J.; Jiang, C.; Cao, X.; Zhao, X.; Zhang, X.; et al. Transcription factor ISL1 is essential for pacemaker development and function. J. Clin. Investig. 2015, 125, 3256–3268.
  22. Hu, W.; Xin, Y.; Hu, J. Shox2: The Role in Differentiation and Development of Cardiac Conduction System. Tohoku J. Exp. Med. 2018, 244, 177–186.
  23. Efe, J.A.; Hilcove, S.; Kim, J.; Zhou, H.; Ouyang, K.; Wang, G.; Chen, J.; Ding, S. Conversion of mouse fibroblasts into cardiomyocytes using a direct reprogramming strategy. Nat. Cell Biol. 2011, 13, 215–222.
  24. Puskaric, S.; Schmitteckert, S.; Mori, A.D.; Glaser, A.; Schneider, K.U.; Bruneau, B.G.; Blaschke, R.J.; Steinbeisser, H.; Rappold, G. Shox2 mediates Tbx5 activity by regulating Bmp4 in the pacemaker region of the developing heart. Hum. Mol. Genet. 2010, 19, 4625–4633.
  25. Wu, L.; Du, J.; Jing, X.; Yan, Y.; Deng, S.; Hao, Z.; She, Q. Bone morphogenetic protein 4 promotes the differentiation of Tbx18-positive epicardial progenitor cells to pacemaker-like cells. Exp. Ther. Med. 2019, 17, 2648–2656.
  26. Moskowitz, I.P.; Kim, J.B.; Moore, M.L.; Wolf, C.M.; Peterson, M.A.; Shendure, J.; Nobrega, M.A.; Yokota, Y.; Berul, C.; Izumo, S.; et al. A molecular pathway including Id2, Tbx5, and Nkx2-5 required for cardiac conduction system development. Cell 2007, 129, 1365–1376.
  27. Nakashima, Y.; Yanez, D.A.; Touma, M.; Nakano, H.; Jaroszewicz, A.; Jordan, M.C.; Pellegrini, M.; Roos, K.P.; Nakano, A. Nkx2-5 suppresses the proliferation of atrial myocytes and conduction system. Circ. Res. 2014, 114, 1103–1113.
  28. Fraidenraich, D.; Stillwell, E.; Romero, E.; Wilkes, D.; Manova, K.; Basson, C.T.; Benezra, R. Rescue of cardiac defects in id knockout embryos by injection of embryonic stem cells. Science 2004, 306, 247–252.
  29. Hu, W.; Xin, Y.; Hu, J.; Sun, Y.; Zhao, Y. Inhibitor of DNA binding in heart development and cardiovascular diseases. Cell Commun. Signal. 2019, 17, 51.
  30. Wiese, C.; Grieskamp, T.; Airik, R.; Mommersteeg, M.T.; Gardiwal, A.; de Gier-de Vries, C.; Schuster-Gossler, K.; Moorman, A.F.; Kispert, A.; Christoffels, V.M. Formation of the sinus node head and differentiation of sinus node myocardium are independently regulated by Tbx18 and Tbx3. Circ. Res. 2009, 104, 388–397.
  31. Eif, V.W.W.v.; Devalla, H.D.; Boink, G.J.J.; Christoffels, V.M. Transcriptional regulation of the cardiac conduction system. Nat. Rev. Cardiol. 2018, 15, 617–630.
  32. van der Harst, P.; van Setten, J.; Verweij, N.; Vogler, G.; Franke, L.; Maurano, M.T.; Wang, X.; Mateo Leach, I.; Eijgelsheim, M.; Sotoodehnia, N.; et al. 52 Genetic Loci Influencing Myocardial Mass. J. Am. Coll. Cardiol. 2016, 68, 1435–1448.
  33. Pfeufer, A.; van Noord, C.; Marciante, K.D.; Arking, D.E.; Larson, M.G.; Smith, A.V.; Tarasov, K.V.; Müller, M.; Sotoodehnia, N.; Sinner, M.F.; et al. Genome-wide association study of PR interval. Nat. Genet. 2010, 42, 153–159.
  34. van Setten, J.; Brody, J.A.; Jamshidi, Y.; Swenson, B.R.; Butler, A.M.; Campbell, H.; Del Greco, F.M.; Evans, D.S.; Gibson, Q.; Gudbjartsson, D.F.; et al. PR interval genome-wide association meta-analysis identifies 50 loci associated with atrial and atrioventricular electrical activity. Nat. Commun. 2018, 9, 2904.
  35. Sotoodehnia, N.; Isaacs, A.; de Bakker, P.I.; Dörr, M.; Newton-Cheh, C.; Nolte, I.M.; van der Harst, P.; Müller, M.; Eijgelsheim, M.; Alonso, A.; et al. Common variants in 22 loci are associated with QRS duration and cardiac ventricular conduction. Nat. Genet. 2010, 42, 1068–1076.
  36. Verweij, N.; Mateo Leach, I.; van den Boogaard, M.; van Veldhuisen, D.J.; Christoffels, V.M.; LifeLines Cohort Study; Hillege, H.L.; van Gilst, W.H.; Barnett, P.; de Boer, R.A.; et al. Genetic determinants of P wave duration and PR segment. Circ. Cardiovasc. Genet. 2014, 7, 475–481.
  37. Hoogaars, W.M.; Engel, A.; Brons, J.F.; Verkerk, A.O.; de Lange, F.J.; Wong, L.Y.; Bakker, M.L.; Clout, D.E.; Wakker, V.; Barnett, P.; et al. Tbx3 controls the sinoatrial node gene program and imposes pacemaker function on the atria. Genes. Dev. 2007, 21, 1098–1112.
  38. Bakker, M.L.; Boink, G.J.J.; Boukens, B.J.; Verkerk, A.O.; van den Boogaard, M.; den Haan, A.D.; Hoogaars, W.M.H.; Buermans, H.P.; de Bakker, J.M.T.; Seppen, J.; et al. T-box transcription factor TBX3 reprogrammes mature cardiac myocytes into pacemaker-like cells. Cardiovasc. Res. 2012, 94, 439–449.
  39. Mommersteeg, M.T.; Hoogaars, W.M.; Prall, O.W.; de Gier-de Vries, C.; Wiese, C.; Clout, D.E.; Papaioannou, V.E.; Brown, N.A.; Harvey, R.P.; Moorman, A.F.; et al. Molecular pathway for the localized formation of the sinoatrial node. Circ. Res. 2007, 100, 354–362.
  40. Espinoza-Lewis, R.A.; Liu, H.; Sun, C.; Chen, C.; Jiao, K.; Chen, Y. Ectopic expression of Nkx2.5 suppresses the formation of the sinoatrial node in mice. Dev. Biol. 2011, 356, 359–369.
  41. Birket, M.; Ribeiro, M.; Verkerk, A.; Ward, D.; Leitoguinho, A.R.; Hartogh, S.C.D.; Orlova, V.V.; Devalla, H.D.; Schwach, V.; Bellin, M.; et al. Expansion and patterning of cardiovascular progenitors derived from human pluripotent stem cells. Nat. Biotechnol. 2015, 33, 970–979.
  42. Greulich, F.; Rudat, C.; Kispert, A. Mechanisms of T-box gene function in the developing heart. Cardiovasc. Res. 2011, 91, 212–222.
  43. Cho, H.C. Pacing the Heart with Genes: Recent Progress in Biological Pacing. Curr. Cardiol. Rep. 2015, 17, 65.
  44. McNally, E.M.; Svensson, E.C. Setting the pace: Tbx3 and Tbx18 in cardiac conduction system development. Circ. Res. 2009, 104, 285–287.
  45. Kapoor, N.; Galang, G.; Marbán, E.; Cho, H.C. Transcriptional suppression of connexin43 by TBX18 undermines cell-cell electrical coupling in postnatal cardiomyocytes. J. Biol. Chem. 2011, 286, 14073–14079.
  46. Kapoor, N.; Liang, W.; Marbán, E.; Cho, H.C. Direct conversion of quiescent cardiomyocytes to pacemaker cells by expression of Tbx18. Nat. Biotechnol. 2013, 31, 54–62.
  47. Hu, Y.F.; Dawkins, J.F.; Cho, H.C.; Marbán, E.; Cingolani, E. Biological pacemaker created by minimally invasive somatic reprogramming in pigs with complete heart block. Sci. Transl. Med. 2014, 6, 245ra94.
  48. Farin, H.F.; Bussen, M.; Schmidt, M.K.; Singh, M.K.; Schuster-Gossler, K.; Kispert, A. Transcriptional repression by the T-box proteins Tbx18 and Tbx15 depends on Groucho corepressors. J. Biol. Chem. 2007, 282, 25748–25759.
  49. Ren, J.; Miao, D.; Li, Y.; Gao, R. Spotlight on Isl1: A Key Player in Cardiovascular Development and Diseases. Front. Cell Dev. Biol. 2021, 9, 793605.
  50. Zhou, Y.; Yang, H.; Shi, J.; Zhang, M.; Yang, S.; Wang, N.; Sun, R.; Wang, Z.; Fei, J. Fate Tracing of Isl1+Cells in Adult Mouse Hearts under Physiological and Exercise Conditions. Int. J. Sports Med. 2019, 40, 921–930.
  51. Tessadori, F.; van Weerd, J.H.; Burkhard, S.B.; Verkerk, A.O.; de Pater, E.; Boukens, B.J.; Vink, A.; Christoffels, V.M.; Bakkers, J. Identification and functional characterization of cardiac pacemaker cells in zebrafish. PLoS ONE 2012, 7, e47644.
  52. Vedantham, V.; Galang, G.; Evangelista, M.; Deo, R.C.; Srivastava, D. RNA sequencing of mouse sinoatrial node reveals an upstream regulatory role for Islet-1 in cardiac pacemaker cells. Circ. Res. 2015, 116, 797–803.
  53. Dorn, T.; Goedel, A.; Lam, J.T.; Haas, J.; Tian, Q.; Herrmann, F.; Bundschu, K.; Dobreva, G.; Schiemann, M.; Dirschinger, R.; et al. Direct nkx2-5 transcriptional repression of isl1 controls cardiomyocyte subtype identity. Stem Cells 2015, 33, 1113–1129.
  54. Hoffmann, S.; Berger, I.M.; Glaser, A.; Bacon, C.; Li, L.; Gretz, N.; Steinbeisser, H.; Rottbauer, W.; Just, S.; Rappold, G. Islet1 is a direct transcriptional target of the homeodomain transcription factor Shox2 and rescues the Shox2-mediated bradycardia. Basic. Res. Cardiol. 2013, 108, 339.
  55. Whitcomb, J.; Gharibeh, L.; Nemer, M. From embryogenesis to adulthood: Critical role for GATA factors in heart development and function. IUBMB Life 2020, 72, 53–67.
  56. Molkentin, J.D.; Lin, Q.; Duncan, S.A.; Olson, E.N. Requirement of the transcription factor GATA4 for heart tube formation and ventral morphogenesis. Genes Dev. 1997, 11, 1061–1072.
  57. Pu, W.T.; Ishiwata, T.; Juraszek, A.L.; Ma, Q.; Izumo, S. GATA4 is a dosage-sensitive regulator of cardiac morphogenesis. Dev. Biol. 2004, 275, 235–244.
  58. Zeisberg, E.M.; Ma, Q.; Juraszek, A.L.; Moses, K.; Schwartz, R.J.; Izumo, S.; Pu, W.T. Morphogenesis of the right ventricle requires myocardial expression of Gata4. J. Clin. Investig. 2005, 115, 1522–1531.
  59. Rivera-Feliciano, J.; Lee, K.H.; Kong, S.W.; Rajagopal, S.; Ma, Q.; Springer, Z.; Izumo, S.; Tabin, C.J.; Pu, W.T. Development of heart valves requires Gata4 expression in endothelial-derived cells. Development 2006, 133, 3607–3618.
  60. Oka, T.; Maillet, M.; Watt, A.J.; Schwartz, R.J.; Aronow, B.J.; Duncan, S.A.; Molkentin, J.D. Cardiac-specific deletion of Gata4 reveals its requirement for hypertrophy, compensation, and myocyte viability. Circ. Res. 2006, 98, 837–845.
  61. Gharibeh, L.; Yamak, A.; Whitcomb, J.; Lu, A.; Joyal, M.; Komati, H.; Liang, W.; Fiset, C.; Nemer, M. GATA6 is a regulator of sinus node development and heart rhythm. Proc. Natl. Acad. Sci. USA 2021, 118, e2007322118.
  62. Gassanov, N.; Er, F.; Zagidullin, N.; Hoppe, U.C. Endothelin induces differentiation of ANP-EGFP expressing embryonic stem cells towards a pacemaker phenotype. FASEB J. 2004, 18, 1710–1712.
  63. Zheng, M.; Erhardt, S.; Ai, D.; Wang, J. Bmp Signaling Regulates Hand1 in a Dose-Dependent Manner during Heart Development. Int. J. Mol. Sci. 2021, 22, 9835.
  64. Firulli, B.A.; George, R.M.; Harkin, J.; Toolan, K.P.; Gao, H.; Liu, Y.; Zhang, W.; Field, L.J.; Liu, Y.; Shou, W.; et al. HAND1 loss-of-function within the embryonic myocardium reveals survivable congenital cardiac defects and adult heart failure. Cardiovasc. Res. 2020, 116, 605–618.
  65. Firulli, B.A.; Fuchs, R.K.; Vincentz, J.W.; Clouthier, D.E.; Firulli, A.B. HAND1 phosphoregulation within the distal arch neural crest is essential for craniofacial morphogenesis. Development 2014, 141, 3050–3061.
  66. Vincentz, J.W.; Toolan, K.P.; Zhang, W.; Firulli, A.B. Hand factor ablation causes defective left ventricular chamber development and compromised adult cardiac function. PLoS Genet. 2017, 13, e1006922.
  67. Kim, K.-H.; Rosen, A.; Hussein, S.M.I.; Puviindran, V.; Korogyi, A.S.; Chiarello, C.; Nagy, A.; Hui, C.-C.; Backx, P.H. Irx3 is required for postnatal maturation of the mouse ventricular conduction system. Sci. Rep. 2016, 6, 19197.
  68. Bakker, M.; Boukens, B.; Mommersteeg, M.; Brons, J.; Wakker, V.; Moorman, A.; Christoffels, V.M. Transcription Factor TBX3 Is Required for the Specification of the Atrioventricular Conduction System. Circ. Res. 2008, 102, 1340–1349.
  69. Briggs, L.E.; Takeda, M.; Cuadra, A.E.; Wakimoto, H.; Marks, M.H.; Walker, A.J.; Seki, T.; Oh, S.P.; Lu, J.T.; Sumners, C.; et al. Perinatal loss of NKX2-5 results in rapid conduction and contraction defects. Radiat. Oncol. 2008, 103, 580–590.
  70. Jay, P.Y.; Harris, B.S.; Maguire, C.T.; Buerger, A.; Wakimoto, H.; Tanaka, M.; Kupershmidt, S.; Roden, D.M.; Schultheiss, T.M.; O’Brien, T.X.; et al. Nkx2-5 mutation causes anatomic hypoplasia of the cardiac conduction system. J. Clin. Investig. 2004, 113, 1130–1137.
  71. Hoogaars, W.M.H.; Tessari, A.; Moorman, A.F.M.; de Boer, P.A.J.; Hagoort, J.; Soufan, A.T.; Campione, M.; Christoffels, V.M. The transcriptional repressor Tbx3 delineates the developing central conduction system of the heart. Cardiovasc. Res. 2004, 62, 489–499.
  72. Moskowitz, I.P.; Pizard, A.; Patel, V.V.; Bruneau, B.G.; Kim, J.B.; Kupershmidt, S.; Roden, D.; Berul, C.I.; Seidman, C.E.; Seidman, J.G. The T-Box transcription factor Tbx5 is required for the patterning and maturation of the murine cardiac conduction system. Development 2004, 131, 4107–4116.
  73. Munshi, N.V. Gene Regulatory Networks in Cardiac Conduction System Development. Circ. Res. 2012, 110, 1525–1537.
  74. Costantini, D.L.; Arruda, E.P.; Agarwal, P.; Kim, K.H.; Zhu, Y.; Zhu, W.; Lebel, M.; Cheng, C.W.; Park, C.Y.; Pierce, S.A.; et al. The homeodomain transcription factor Irx5 establishes the mouse cardiac ventricular repolarization gradient. Cell 2005, 123, 347–358.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
This entry is offline, you can click here to edit this entry!
ScholarVision Creations
Feedback